Buy Pfizer India; target of Rs 5655: Anand Rathi

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Anand Rathi's research report on Pfizer India

On its better hospitals and vaccine performances, Pfizer’s Q3 FY21 sales grew 10.3% y/y to Rs.5.9bn. Its gross margin expanded 149bps y/y to 64.2%, while the EBITDA margin expanded 836bps y/y to 33.2% on account of lower promotional costs. Lower other income and a higher tax rate reduced adj. PAT growth to 19.8% (Rs.1.4bn). We expect sales growth of key brands (Gelusil, Prevenar-13, Becosules, Magnex, Dolonex and Meronem) to accelerate in FY22. The stock trades at attractive valuations of 36x/31.7x FY22e/FY23e earnings.

Outlook

We upgrade our rating to a Buy with a target of Rs.5,655.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More